Department of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Family Nursing, Faculty of Medicine, Graduate School of Health Sciences and Nursing, The University of Tokyo, Tokyo, Japan.
Jpn J Clin Oncol. 2020 Jul 9;50(7):787-793. doi: 10.1093/jjco/hyaa036.
The MD Anderson Symptom Inventory for Brain Tumor (MDASI-BT) module is a widely used instrument for measuring symptom burden and interference of daily activities in brain tumor patients. This study aims to develop and validate its Japanese version (MDASI-BT-Japanese).
Following forward and backward translation of the original MDASI-BT into Japanese, understandability and feasibility were assessed by cognitive debriefing. Subsequently, patients with brain tumors were asked to fill out MDASI-BT-Japanese and European Quality of Life-5 Dimensions (EQ-5D). Feasibility, reliability and validity of MDASI-BT-Japanese were assessed.
Cognitive debriefing confirmed overall ease of completion and good understandability. The study population composed of 140 patients with brain tumors (most commonly gliomas). The mean symptom severity score and mean interference score were 1.9 ± 1.7 and 2.8 ± 2.7, respectively. The top items included distress and drowsiness for symptom severity and general activity and work for interference. The median time required was 4 minutes (range, 0.5-30), and missing values were seen in 1%. Internal consistency was proven by excellent Cronbach's coefficient alpha (0.94 for symptom severity, 0.92 for interference). Test-retest reliability was assessed with acceptable intra-class correlation coefficient (mean, 0.76). Correlation efficient ranged between 0.7 and 0.9 for convergent validity. Known-group validity was confirmed by significantly different mean symptom severity score and mean interference score among patients with different performance status. As evidence of concurrent validity, MDASI-BT-Japanese correlated with EQ-5D in the hypothesized magnitude and direction.
The newly developed MDASI-BT-Japanese has demonstrated feasibility, reliability and validity in evaluation of clinical benefit in Japanese-speaking brain tumor patients.
MD Anderson 脑肿瘤症状量表（MDASI-BT）模块是一种广泛用于测量脑肿瘤患者症状负担和日常活动干扰的工具。本研究旨在开发和验证其日文版（MDASI-BT-Japanese）。
对原始 MDASI-BT 进行正向和反向翻译后，通过认知访谈评估理解性和可行性。随后，要求脑肿瘤患者填写 MDASI-BT-Japanese 和欧洲五维健康量表（EQ-5D）。评估 MDASI-BT-Japanese 的可行性、信度和效度。
认知访谈证实了整体完成的容易程度和良好的理解性。研究人群由 140 名脑肿瘤患者（最常见的是胶质瘤）组成。平均症状严重程度评分为 1.9±1.7，平均干扰程度评分为 2.8±2.7。排名靠前的项目包括症状严重程度的困扰和困倦，以及干扰程度的一般活动和工作。所需的中位数时间为 4 分钟（范围 0.5-30 秒），缺失值为 1%。内部一致性由极好的 Cronbach's 系数 alpha（症状严重程度为 0.94，干扰为 0.92）证明。通过可接受的组内相关系数（平均为 0.76）评估测试-重测信度。与认知障碍、抑郁、疼痛、疲劳和恶心相关的症状严重程度和干扰程度的收敛效度范围在 0.7 到 0.9 之间。在不同表现状态的患者中，症状严重程度评分和干扰程度评分的差异证实了已知组别的有效性。作为同时效度的证据，MDASI-BT-Japanese 与 EQ-5D 在假设的幅度和方向上相关。
新开发的 MDASI-BT-Japanese 在评估日语脑肿瘤患者的临床获益方面表现出了可行性、信度和效度。
